D.J.A. Eckland
Diurnal (United Kingdom) · 51 works · 6,212 citations · h-index 21
Top works
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
- Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress
- CAPTOPRIL: REVERSIBLE RENAL FAILURE WITH SEVERE HYPERKALÆMIA
- Clinical pharmacokinetics of pioglitazone
- Inhibition of Hypothalamic Thyrotropin-Releasing Hormone Messenger Ribonucleic Acid during Food Deprivation*
- Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease.
- 35th Annual Meeting of the European Association for the Study of Diabetes
- Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
- Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant‐induced arthritis
- A pituitary tuberculoma.
- A Phase 2 Study of Chronocort, a Modified-Release Formulation of Hydrocortisone, in the Treatment of Adults With Classic Congenital Adrenal Hyperplasia
- Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study
- Salivary Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After Hydrocortisone
- Osmotic regulation of hypothalamo-neurointermediate lobe corticotrophin-releasing factor-41 in the rat
- Somatostatin and Thyrotrophin‐Releasing Hormone Response and Receptor Status of a Thyrotrophin‐Secreting Pituitary Adenoma: Clinical and in vitro Studies
- Managing the burden of Type 2 diabetes: an international survey of physicians
- Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes
- Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: A pilot study
- Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non—insulin-dependent diabetes mellitus
- Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients